The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized...

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• Convalescent plasma therapy (CPT) is an emergency treatment for viral infections, providing passive immunity.
• During the COVID-19 pandemic, CPT was widely used for its potential to deliver SARS-CoV-2 antibodies.
• Limited research has specifically evaluated CPT's impact on hospitalization duration.

Purpose of the Study:

• To assess the effect of CPT on the length of hospital stay (LOS) in patients with moderate COVID-19.
• To determine if CPT can shorten the duration of care in Emergency Room (ER) and High Care Unit (HCU).

Main Methods:

• A single-blind randomized controlled trial (RCT) involving 30 moderate COVID-19 patients (age 18-75).
• Patients received either CPT plus standard care or standard care alone (1:1 ratio).
• Primary outcome was the length of stay in ER and HCU, analyzed using independent T-tests.

Main Results:

• The CPT group experienced significantly shorter LOS in both ER (mean difference: -32.7 hours) and HCU (mean difference: -33.3 hours) compared to controls (p<0.001).
• Neutralizing antibodies in CPT are believed to inhibit viral replication and accelerate recovery.
• No adverse events were reported in either treatment group.

Conclusions:

• CPT administration may decrease the length of hospital stay for moderate COVID-19 patients.
• A small sample size necessitates larger studies to confirm generalizability.
• Early CPT implementation could enhance patient management and healthcare resource utilization.